ONCOLOGIC OUTCOMES OF MAINTENANCE BCG VERSUS MAINTENANCE GEMCITABINE/DOCETAXEL AFTER INDUCTION BCG FOR NON-MUSCLE-INVASIVE BLADDER CANCER | AMiner